White Papers

Today, Leavitt Partners released “Using Modeling to Project Herd Immunity: When and how we will get back to normal,” a research paper outlining results from their current model to determine the expected timeline to reaching herd immunity from COVID-19. The research was conducted in response to growing interest in understanding variables driving national progress to … Continue reading

Cell and gene therapies (CGTs) are some of the most promising and exciting medical advancements taking place today. Some existing CGTs treat previously untreatable rare diseases, and there are hundreds of CGTs in clinical development to treat various types of cancer, hemophilia, sickle cell and other blood disorders, Alzheimer’s disease, and numerous rare conditions. The … Continue reading

Today, Leavitt Partners released “COVID-19 Hotspots,” a white paper that informs policymakers, industry leaders, and other key stakeholders to quickly assess where to deploy resources during the ongoing pandemic, and the accompanying, free tool that provides a daily updated map of where COVID-19 hotspots are forming in the United States. The authors discuss the nuances … Continue reading

Today, Leavitt Partners released “Understanding the Coronavirus & Situational Characteristics: A Framework for Individuals and Businesses for Mitigating Risk,” a white paper informed by contagion principles of the virus that provides opportunities for creative interventions. The paper walks through virus transmission and key principles for reducing spread, as well as assessing situational characteristics to mitigate … Continue reading

Salt Lake City, March 20, 2019—Today, Leavitt Partners released “Multi-Year Medicare Advantage Plans: A Framework for Action.” This white paper proposes a Multi-Year Medicare Advantage Plan (MyMap) demonstration project to remove barriers to a value-based health insurance products, improve health outcomes for Medicare beneficiaries, and reduce the cost of care. The white paper is authored … Continue reading